uniQure Announces Multiple Company Presentations at Upcoming November Conferences
October 31 2017 - 04:09PM
YASTEST
LEXINGTON, Mass. and AMSTERDAM, the
Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- uniQure
N.V. (NASDAQ:QURE), a leading gene therapy company advancing
transformative therapies for patients with severe medical needs,
today announced company presentations at the following conferences
taking place in November:
Gene Therapy
for Rare Disorders, November 1 -2, 2017, at the Hilton London
Olympia in London, United Kingdom.
- Sander van Deventer, M.D., Ph.D.,
chief scientific officer, will be presenting the keynote
presentation: "Investigating Critical Challenges in the Gene
Therapy Field", on Wednesday November 1st, at 8:30 a.m. GMT. In
addition, he will be participating in a panel discussion: "How do
Investors View the Gene Therapy Space?" on Thursday November
2nd at 2:00 p.m. GMT.
Life Science
Summit by Defined Health, November 1 - 2, 2017, at 10 on the Park
at Time Warner Center in New York City, NY.
- Jonathan Garen, chief business
officer, will participating in the panel discussion: "Put Your
Money Where Your Heart Is - Investing in Novel Cardiovascular
Therapies in Myocardial Infarction, Heart Failure and Peripheral
Artery Disease" on Wednesday, November 1st, 2017 at 1:15 p.m.
EST.
Huntington's
disease Study Group, November 2 - 4, 2017, at the at the Hyatt
Regency Conference Center in Denver, Co.
- Pavlina Konstantinova, Ph.D.,
director new therapeutic target discovery, will be presenting on
AAV5-miHTT gene therapy for Huntington's Disease on Thursday
November 2nd, at 6:00 p.m. EDT.
10th Global
Forum on Research and Treatment Products for Bleeding Disorders,
November 8 - 10, 2017, at the Marriott Château Champlain hotel in
Montreal, Canada.
- Eileen Sawyer Ph.D., director global
medical affairs, will be presenting Interim results up to 1.5
years' follow-up from a Phase I/II dose-escalation study of AMT-060
(AAV5-hFIX) in adults with severe or moderate-severe hemophilia B
on Friday, November 10th at 8:30 a.m. EST.
2017 BioMAN
Summit on Commercialization of Cell and Gene Therapy Products: The
Impact of Critical Choices, November 14- 15, 2017, at the Boston
Marriott Cambridge in Boston, MA.
- Lance Weed, vice president
operations, will be presenting on the Development and
Commercialization of Cell Therapy Products.
Evercore ISI
Inaugural Biopharma Catalyst/Deep Dive Conference, November 29 -
30, 2017, at the Boston Harbor Hotel in Boston, MA.
- Matthew Kapusta, chief executive
officer, will be hosting investor meetings and participating in a
fireside chat on Wednesday November 29th, at 4:15 p.m. EST The live
webcast can be accessed through the link displayed in the Investor
section of the uniQure website. The webcast replay will be
available for at least two weeks following the live event.
Barclays
Gene Editing & Gene Therapy Summit Conference, November 30,
2017, at Barclays offices at 745 Seventh Avenue in New York City,
NY.
- Matthew Kapusta, chief executive
officer, will be hosting investor meetings and presenting a
corporate overview on Thursday November 30th, at 8:20 a.m.
EST.
About
uniQure
uniQure is delivering on the promise of gene therapy - single
treatments with potentially curative results. We are leveraging our
modular and validated technology platform to rapidly advance a
pipeline of proprietary and partnered gene therapies to treat
patients with hemophilia, Huntington's disease and cardiovascular
diseases. www.uniQure.com
uniQure
Contacts:
For
Investors:
Maria E.
Cantor
Direct:
339-970-7536
Mobile:
617-680-9452
m.cantor@uniQure.com
Eva M. Mulder
Direct: +31 20 240
6103
Mobile: +31 6 52 33 15
79
e.mulder@uniQure.com
For Media:
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: uniQure N.V. via Globenewswire
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Feb 2024 to Mar 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2023 to Mar 2024